Login to Your Account



GSK Bolsters Electroceutical Position with $50M Investment

By Nuala Moran
Staff Writer

Wednesday, August 21, 2013
LONDON – Glaxosmithkline plc (GSK) has put further flesh on its ambition to become a leader in electroceuticals – in which nanoscale devices will be used to modulate the body's neural circuits – with the announcement of a $50 million venture capital fund to back pioneers in the field.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription